Bionano Genomics, Inc. (BNGO) vs Karyopharm Therapeutics Inc. (KPTI)
A side-by-side comparison of Bionano Genomics, Inc. and Karyopharm Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BNGO
Bionano Genomics, Inc.
$1.46HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT
KPTI
Karyopharm Therapeutics Inc.
$0.68HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT
Total return — BNGO vs KPTI
growth of $100 · dividends reinvested · last 8yBNGO -100.0% (-62.5%/yr)KPTI -99.7% (-52.5%/yr)KPTI compounded faster over this window
Log scale — wide-divergence pair
BNGO KPTI
BNGO vs KPTI: by the numbers
- •BNGO is the larger company ($17M vs $15M market cap).
- •Both run net losses; BNGO's is the smaller (-106.58% vs -153.28% net margin).
- •BNGO grew revenue faster over the past five years (17.97% vs 7.47% CAGR).
Metrics side by side
Valuation
| Metric | BNGO | KPTI |
|---|---|---|
| P/S ratio | 0.56 | 0.11 |
| P/B ratio | 0.53 | N/A |
Profitability
| Metric | BNGO | KPTI |
|---|---|---|
| Gross margin | 21.95% | 95.88% |
| Operating margin | -116.95% | -56.17% |
| Net margin | -106.58% | -153.28% |
| ROE | -101.76% | N/A |
| ROIC | -85.72% | N/A |
Growth (annualized)
| Metric | BNGO | KPTI |
|---|---|---|
| Revenue CAGR (5Y) | 17.97% | 7.47% |
| Total return CAGR (5Y) | -78.37% | -62.18% |
Frequently asked
- Which has grown faster, BNGO or KPTI?
- Over the past five years, BNGO grew revenue faster — BNGO at a 17.97% CAGR versus KPTI at 7.47%.
- How have BNGO and KPTI total returns compared?
- Over the past 5 years, BNGO delivered -78.37% and KPTI delivered -62.18% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bionano Genomics ROEKaryopharm Therapeutics ROEBionano Genomics operating marginKaryopharm Therapeutics operating marginBionano Genomics revenue growthKaryopharm Therapeutics revenue growthBionano Genomics free cash flowKaryopharm Therapeutics free cash flow
Bionano Genomics & Karyopharm Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.